Botta M - Search Results

1

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.

Santucci MA, Mancini M, Corradi V, Lacobucci I, Martinelli G, Botta M, Schenone S. Santucci MA, et al. Among authors: botta m. Invest New Drugs. 2010 Dec;28(6):876-8. doi: 10.1007/s10637-009-9294-9. Epub 2009 Jul 24. Invest New Drugs. 2010. PMID: 19629392 No abstract available.

2

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.

Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M. Santucci MA, et al. Among authors: botta m. ChemMedChem. 2009 Jan;4(1):118-26. doi: 10.1002/cmdc.200800320. ChemMedChem. 2009. PMID: 19039816

3

A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.

Mancini M, Corradi V, Petta S, Barbieri E, Manetti F, Botta M, Santucci MA. Mancini M, et al. Among authors: botta m. J Pharmacol Exp Ther. 2011 Mar;336(3):596-604. doi: 10.1124/jpet.110.172536. Epub 2010 Nov 1. J Pharmacol Exp Ther. 2011. PMID: 21041536

4

Synthetic SRC-kinase domain inhibitors and their structural requirements.

Schenone S, Manetti F, Botta M. Schenone S, et al. Among authors: botta m. Anticancer Agents Med Chem. 2007 Nov;7(6):660-80. doi: 10.2174/187152007784111269. Anticancer Agents Med Chem. 2007. PMID: 18045061

5

Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.

Radi M, Crespan E, Botta G, Falchi F, Maga G, Manetti F, Corradi V, Mancini M, Santucci MA, Schenone S, Botta M. Radi M, et al. Among authors: botta m, botta g. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11. doi: 10.1016/j.bmcl.2007.11.112. Epub 2007 Dec 4. Bioorg Med Chem Lett. 2008. PMID: 18078752

6

Novel dual Src/Abl inhibitors for hematologic and solid malignancies.

Schenone S, Brullo C, Musumeci F, Botta M. Schenone S, et al. Among authors: botta m. Expert Opin Investig Drugs. 2010 Aug;19(8):931-45. doi: 10.1517/13543784.2010.499898. Expert Opin Investig Drugs. 2010. PMID: 20557276 Review.

7

Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis.

Corradi V, Mancini M, Manetti F, Petta S, Santucci MA, Botta M. Corradi V, et al. Among authors: botta m. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6133-7. doi: 10.1016/j.bmcl.2010.08.019. Epub 2010 Aug 8. Bioorg Med Chem Lett. 2010. PMID: 20832303

8

Allosteric inhibitors of Bcr-Abl: towards novel myristate-pocket binders.

Radi M, Schenone S, Botta M. Radi M, et al. Among authors: botta m. Curr Pharm Biotechnol. 2013;14(5):477-87. doi: 10.2174/138920101405131111103750. Curr Pharm Biotechnol. 2013. PMID: 22429131 Review.

9

An update on dual Src/Abl inhibitors.

Musumeci F, Schenone S, Brullo C, Botta M. Musumeci F, et al. Among authors: botta m. Future Med Chem. 2012 Apr;4(6):799-822. doi: 10.4155/fmc.12.29. Future Med Chem. 2012. PMID: 22530642 Review.

10

A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors.

Manetti F, Locatelli GA, Maga G, Schenone S, Modugno M, Forli S, Corelli F, Botta M. Manetti F, et al. Among authors: botta m. J Med Chem. 2006 Jun 1;49(11):3278-86. doi: 10.1021/jm060236z. J Med Chem. 2006. PMID: 16722646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

734 results

Search Page

Filters